A Working-Day Evaluation of Dyslipidaemia in a Spanish Population (JADE Study)
Tóm tắt
Objective: The JADE (Jornada de Análisis de Dislipemias en España) study aimed to analyse the impact of dyslipidaemia and other cardiovascular risk factors in primary care and to establish the attitude of physicians in treating dyslipidaemic patients.
Participants and Methods: The JADE study was an observational study conducted in primary care centres throughout the Spanish territory over 1 day of activity. Physicians recorded the data of each patient who visited on the day selected and who provided laboratory tests on a previous visit (i.e. for reasons not related to the study) including the measurement of some lipid parameters. 3841 physicians participated, and collected information from 10 641 patients, of whom 7832 met predefined criteria for dyslipidaemia (73.6%).
Results and Conclusion: In the group of patients with dyslipidaemia, 55.6% of patients received lipid-lowering treatment. When the degree of control achieved by patients on lipid-lowering drug treatment was analysed, it was found that only 14.7% had ideal low density lipoprotein levels, while in the group of patients considered to be nondyslipidaemic, 38.1% met criteria for lipid-lowering drug intervention but were not receiving treatment. Therefore, it would be advisable to perform programmes promoting the better diagnosis and treatment of dyslipidaemias.
Tài liệu tham khảo
Uemura K, Pisa Z. Trends in cardiovascular disease mortality in industrialized countries since 1950. World Health Stat Q 1988; 41: 155–78
Kannel W B, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 1976; 38(1): 46–51
Keys A. Coronary heart disease in seven countries. Circulation 1970; 41: 1–211
Grimm Jr RH, Cohen JD, Smith WM, et al. Hypertension management in the Multiple Risk Factor Intervention Trial (MRFIT). Six-year intervention results for men in special intervention and usual care groups. Arch Intern Med 1985; 145(7): 1191–9
Cohen JD. Abnormal electrocardiograms and cardiovascular risk: role of silent myocardial ischemia. Evidence from MRFIT. Am J Cardiol 1992; 16; 70(16): 14F–18F
Assmann G, Schulte H, Cullen P. New and classical risk factors—the Munster heart study (PROCAM). Eur J Med Res 1997.16; 2(6): 237–42
Assman G. Lipid metabolism disorders and coronary heart disease: primary prevention, diagnosis, and therapy guidelines for general practice. 2nd ed. München: MMV-Medizin-Verl, 1993
Mannimen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentration on coronary heart disease risk in the Helsinki Heart Study. Implication for treatment. Circulation 1992; 85: 37–45
European Atherosclerosis Society Study Group. Strategies for the prevention of coronary heart disease: a policy statement of the European Atherosclerosis Society. Eur Heart J 1987; 8: 77–88
NCEP. National Cholesterol Education Program Report of the expert Panel of Population Strategies for Blood Cholesterol Reduction. Washington D.C: National Heart Lung and Blood Instituto, 1990
The Expert Panel. Summary of the second report of National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and treatment of high Blood Cholesterol in adults (Adult Treatment Panel 11) JAMA 1993; 269: 3015–23
Sociedad Española de Arteriosclerosis, Sociedad Española de Medicina Interna y Liga para la Lucha contra la Hipertensión Arterial. Recomendaciones para la prevenciön primaria de la enfermedad cardiovascular. Clin Invest Arteriosclerosis 1994; 6: 62-102
Banegas JR, Rodríguez Artalejo F, Rodríguez Pérez P, et al. Recent coronary heart disease mortality trends in Spain. Int J Epidemiol 1990; 19: 761–2
Banegas JR, Rodríguez F, Villar F, et al. Perspectiva epidemiológica del riesgo cardiovascular en España. Iberoamerican J Epidemiol 1996; 1: 40–5
Plans P, Pardell H, Salieres L. Epidemiology of cardiovascular risk factors in Catalonia. Spain. Eur J Epidemiol 1993; 9(4): 381–9
Tresserras R, Pardell H. Cardiovascular mortality trends in Spain and Catalonia. Comparisons with Europe. Eur J Clin Nutr 1993; 47Suppl. 1: S42–6
Gómez Geríque JA. Situación actual del tratamiento hipolipemiante en España. Clin Invest Arteriosclerosis 1997; 9Suppl. 2: 28–38
Stafford RS, Blumenthal D, Pasternak RC. Variations in cholesterol management practices of US Physicians. J Am Coll Cardiol 1997; 29: 139–46
Shepherd J, Cobbe SM, Ford I, et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–7
Downs JR, Clearfield M, Weis S, et al., for the AFCAPS/ TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615–22
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet` 1994; 344: 1383–9
Sacks FM, Pfeffer MA, Moye LA, et al., for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol level. N Engl J Med 1996; 335: 1001–9
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 Nov 5; 339(19): 1349–57
Plans P, Ruigomez J, Pardell H, et al. Lipid distribution in the adult population of Catalonia. Rev Clin Esp 1993; 193(1): 35–42
Ferreiros MC, Cabrera P. Prevalencia de hiperlipemia en el área sanitaria sur de Lugo. Clin Invest Arteriosclerosis 1991; 3Suppl. 1: 11–3
Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986; 256: 2835–8
Stamler J, Wentwoth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factors Intervention Trial (MRFIT). JAMA 1986; 256: 2823–8
Lipid Research Clinics Program Epidemiology Committee: Plasma Lipid distribution in selected North America population. The Lipid Research Clinics Prevalence Study. Circulation 1979; 60: 427-39
Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998; 19Suppl. A: A2–A11
Dannenberg AL, Garrison RJ, Kannel WB. Incidence of hypertension in the Framingham Study. Am J Public Health 1988; 78: 676–9
Myers RH, Kiely DK, Cupples LA, et al. Parental history is an independent risk factor for coronary artery disease: the Framingham Study. Am Heart J 1990; 120: 963–9
Rosseneu M, Fruchart JC, Bard JM. Plasma lipoprotein concentrations in young adults with a parental history of premature coronary heart disease and in control subjects. The EARS Study. Circulation 1994; 89: 1967–73
Recommendations of the Second Joint Task Force of the European and other Societies on Coronary Prevention. Prevention of coronary heart disease in clinical practice. Eur Heart J 1998; 19: 1434–503
EUROASPIRE Study group. A European Society of Cardiology Survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997; 18: 1569–82
de Velasco JA, Cosin J, Sendon JL, et al. Prevención secundaria del infarto de miocardio en España. El estudio PREVESE. Rev Esp Cardiol 1997; 50: 406–15
Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996; 164: 208–11
Unwin N, Thomson R, O’Byrne AM, et al. Implications of applying widely accepted cholesterol screening and management guidelines to a British adult population: cross sectional study of cardiovascular disease and risk factors. BMJ 1998; 317: 1125–30
Ramsay LE, Wallis EJ, Haq IU, et al. Use of statins. Sheffield table is useful. BMJ 1998 Aug 15; 317(7156): 473–4
Stein Y. Comparison of European and USA guidelines for prevention of coronary heart disease. Atherosclerosis 1994; 110 Oct; Suppl.: S41–S44
Hiatt JC, Shamsie SG, Schectman G. Discontinuation rates of cholesterol-lowering medications: implications for primary care. Am J Manag Care 1999; 5: 437–44
Shepherd J. From best evidence to best practice —what are the obstacles? Atherosclerosis 1999; 147(SI): S45–S51
Piñeiro F, Gil V, Pastor R, et al. Noncompliance with programmed appointments in dyslipidemia patients in pharmacologic treatment. Aten Primaria 1999; 24: 19–25
Piñeiro F, Gil V, Pastor R, et al. Factors involved in the non-compliance of pharmacologic treatment of dyslipidemia. Aten Primaria 1998; 21: 425–30
Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES Study). Am J Cardiol 1998; 81: 582–7
Dart A, Jerums G, Nicholson G, et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997; 80: 39–44
Davidson M, McKenney J, Stein E, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol 1997; 79: 1475–81
Bertolini S, Bittolo Bon G, Campbell LM. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 1997; 130: 191–7